Wave Life Sciences hits tumultuous waters as ax comes crashing down on staffers

In an SEC filing, Wave Life Sciences announced it will cut its staff by nearly a quarter after a difficult few months.


At the end of 2019, Wave announced it was throwing out its experimental drug suvodirsen in Duchenne muscular dystrophy (DMD). Then its shares sunk by more than half, as it cut all other DMD work. A few weeks later, trial results from its other major program in Huntington’s disease further disappointed investors, causing its shares to drop again. Now, the company is looking to make cuts to save cash.



Leave a Reply

Your email address will not be published.

More in News & Trends
The 10 most-anticipated drug launches of 2020

Thanks to EvaluatePharma, FiercePharma was able to assemble a list of the top 10 most-anticipated new drug launches of 2020...